Chlorophyllin is a semi-synthetic derivative of chlorophyll, the green pigment found in plants that is essential for photosynthesis.
-Antioxidant Activity
-Detoxification
-Inhibition of Tumor Growth(unknown pathway?)
-Modulation of Gene Expression
-Anti-inflammatory Effects
Dose: 100-300mg/d split 1-3x/d
Chlorophyllin — Chlorophyllin is a semi-synthetic, water-soluble copper-containing derivative mixture of plant chlorophyll, most commonly used as sodium copper chlorophyllin. It is best classified as a semi-synthetic small-molecule phytochemical derivative that also functions as a food color additive, OTC deodorant drug ingredient, and chemopreventive “interceptor” candidate rather than a validated systemic anticancer drug. Standard abbreviations include CHL and, for the common oral form, SCC (sodium copper chlorophyllin). It originates from natural chlorophyll after saponification and copper substitution to improve water solubility and stability. The strongest translational evidence is for oral reduction of carcinogen bioavailability and DNA-adduct burden in exposure settings; direct tumoricidal signaling effects are mostly preclinical, and photodynamic use is a distinct external-trigger application.
Chlorophyll (Chl), the parent compound of CHL, is readily available by consumption of green vegetables.
Primary mechanisms (ranked):
- Direct carcinogen interception and complex formation in the gut or exposure interface, lowering absorption of mutagens/carcinogens and downstream DNA adduct formation.
- Reduction of xenobiotic activation and genotoxic burden, including modulation of CYP1A1/CYP1B1-related carcinogen handling in exposed epithelial models.
- Direct antiproliferative signaling in cancer cells, especially ERK deactivation with cyclin D1 depletion, leading to cell-cycle arrest and apoptosis in preclinical models.
- Suppression of inflammatory survival signaling, including NF-κB-linked programs, in preclinical carcinogenesis models.
- Photosensitizer-mediated ROS cytotoxicity under light activation in chlorophyllin-assisted photodynamic therapy.
Bioavailability / PK relevance: Oral chlorophyllin is relatively digestive-stable and can interact with intestinal cells, but available PK data suggest limited systemic serum exposure, with significant luminal retention and efflux likely contributing to its dominant gastrointestinal interception profile. Some animal work suggests tissue distribution can occur, but standard oral use does not support assuming high free systemic tumor exposure.
In-vitro vs systemic exposure relevance: Common direct anticancer in-vitro studies likely use concentrations above what is reliably achievable in systemic circulation with ordinary oral dosing. Its most credible non-PDT human effect is not high plasma tumor exposure but reduced carcinogen uptake and biomarker damage. In PDT contexts, efficacy is not ordinary concentration-driven alone and requires an external light trigger.
Clinical evidence status: Human evidence is strongest for chemopreventive biomarker modulation, including a randomized placebo-controlled trial showing reduced aflatoxin biomarker burden in a high-risk population. Evidence for direct cancer treatment remains preclinical or adjunctive/emerging, while newer studies in radiation-related injury are not yet proof of anticancer efficacy.
Mechanistic table
| Rank |
Pathway / Axis |
Cancer Cells |
Normal Cells |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
Carcinogen interception and uptake blockade |
↓ carcinogen delivery to premalignant or exposed cells |
↓ luminal mutagen uptake; ↓ systemic carcinogen burden |
P-R |
Chemoprevention |
Best-supported core mechanism. Chlorophyllin forms non-covalent complexes with carcinogens such as aflatoxin and PAH-related mutagens, lowering bioavailability and downstream DNA damage. |
| 2 |
Xenobiotic activation and DNA adduct burden |
↓ DNA adduct formation; ↓ CYP1A1/CYP1B1-related activation (model-dependent) |
↓ genotoxic burden in exposed epithelia |
R-G |
Genome protection |
Supported in exposed human epithelial models and biomarker studies; strongest in prevention/exposure settings rather than established tumors. |
| 3 |
ERK Cyclin D1 cell-cycle survival axis |
ERK ↓; cyclin D1 ↓; apoptosis ↑ |
↔ unclear |
G |
Cytostasis and apoptosis |
Direct anticancer signaling is reported in breast cancer cell models, but this sits below interception in translational centrality because human systemic exposure appears limited. |
| 4 |
NF-κB inflammatory survival signaling |
NF-κB ↓; inflammatory survival tone ↓ |
Inflammatory injury tone ↓ |
R-G |
Anti-inflammatory anticarcinogenic support |
Relevant mainly in carcinogenesis and tissue-injury models. More supportive than defining as a stand-alone tumor mechanism. |
| 5 |
Mitochondrial ROS increase under photodynamic activation |
↑ ROS (requires external trigger); apoptosis/necrosis ↑ |
↔ or ↑ phototoxicity if illuminated |
P-R |
Photodynamic tumor killing |
This is a distinct modality-specific use case. ROS generation is mechanistically important for chlorophyllin-assisted PDT, but not a generic baseline oral chlorophyllin effect. |
| 6 |
Clinical Translation Constraint |
Systemic monotherapy relevance limited |
Generally favorable oral safety at conventional use levels |
G |
Delivery constraint |
Main constraints are limited systemic exposure, prevention-skewed evidence base, and the fact that strongest human data concern carcinogen interception biomarkers rather than tumor regression. PDT use additionally depends on light delivery geometry. |
TSF legend: P: 0–30 min
R: 30 min–3 hr
G: >3 hr
|